Blog
Follow us for the latest trends, insights and innovations in the pharmaceutical industry.
Orforglipron vs Retatrutide: A Tale of Two Next-Generation GLP-1s
Orforglipron vs retatrutide: oral small‑molecule GLP‑1 agonist vs triple‑hormone injectable. Phase 3 weight loss data, dosing schedules, side effects, regulatory status, and API manufacturing differences.
Read More →
Regulatory Differences Between API and Intermediate Manufacturing: A Practical Guide
Regulatory differences between API and intermediate manufacturing under ICH Q7, FDA, EMA, and NMPA. GMP boundaries, DMF filing, starting material justification.
Read More →
Finerenone Drug Class: What Makes This MRA Different from the Rest
Finerenone drug class: third‑generation non‑steroidal MRA. Compare selectivity, potency, half‑life, and safety vs spironolactone/eplerenone. FDA‑approved for CKD+T2D and HF with LVEF ≥40%.
Read More →
Finerenone Mechanism of Action: A Non-Steroidal MRA Built Differently
Finerenone mechanism of action: a non‑steroidal mineralocorticoid receptor antagonist with high MR selectivity, balanced cardiorenal distribution, no active metabolites, and lower hyperkalemia risk vs steroidal ...
Read More →